No Data
Vcanbio Cell & Gene Engineering (SHSE:600645) Seems To Use Debt Quite Sensibly
Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. Report for the third quarter of 2024
vcanbio cell & gene engineering corp.,ltd. (600645.SH) released its performance for the first three quarters, with a net income of 0.134 billion yuan, a year-on-year increase of 0.76%.
vcanbio cell & gene engineering corp.,ltd. (600645.SH) disclosed its third quarter report for 2024, achieving operating income in the first three quarters...
vcanbio cell & gene engineering corp.,ltd. (600645.SH): VUM02 injection receives drug clinical trial approval notice.
GeLongHui, September 9th | vcanbio cell & gene engineering corp.,ltd. (600645.SH) announced that its wholly-owned subsidiary wuhan guanggu vcan pharmaceutical co.,ltd. received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the approval of VUM02 injection for the treatment of systemic sclerosis on September 9. VUM02 injection (human umbilical cord mesenchymal stem cell injection) is a freeze-preserved stem cell preparation independently developed by the company, which is a new drug of human umbilical cord mesenchymal stem cells (UC-MSC) prepared from screened healthy newborn umbilical cord tissue through in vitro separation, amplification, harvesting, and cryopreservation, with clinical intentions.
Vcanbio Cell & Gene Engineering's (SHSE:600645) Soft Earnings Don't Show The Whole Picture
Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. 2024 Semi-Annual Report
The Five-year Loss for Vcanbio Cell & Gene Engineering (SHSE:600645) Shareholders Likely Driven by Its Shrinking Earnings
